Patents by Inventor Shuichiro Sato
Shuichiro Sato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240153330Abstract: A system for automatically opening a gate of a public transport station may comprise a plurality of transmitters (1201, 1301), a mobile device (1100) of a passenger reaching the plurality of gates and a plurality of gate control devices (1210, 1310) controlling the plurality of gates (1200, 1300). Each transmitter may be installed at one of a plurality of gates (1200, 1300) and may send a transmitter signal including a gate identifier identifying the respective gate. The passenger's mobile device (1100) may receive a plurality of transmitter signals from the plurality of transmitters (1201, 1301), select one of the plurality of received transmitter signals based on a signal characteristic of the received transmitter signals, read the gate identifier included in the selected transmitter signal, and transmit a validation signal including the gate identifier of the selected transmitter signal and a user identifier of the passenger's mobile device (1100) to the plurality of gate control devices (1210, 1310).Type: ApplicationFiled: March 17, 2022Publication date: May 9, 2024Inventors: Satoru HARADA, Shuichiro SAKIKAWA, Yutaka SATO
-
Publication number: 20240140768Abstract: A lifting and lowering movement control system for controlling an automatic conveyance vehicle configured to move with an article loaded thereon and a lifting and lowering device configured to move up and down in a state in which the automatic conveyance vehicle is on board, the system includes a lifting and lowering relevant information acquisition section configured to acquire lifting and lowering relevant information relating to the lifting and lowering device scheduled to be boarded by the automatic conveyance vehicle, and a movement control section configured to set a movement path to the lifting and lowering device scheduled to be boarded based on the lifting and lowering relevant information.Type: ApplicationFiled: March 11, 2021Publication date: May 2, 2024Applicant: FUJI CORPORATIONInventors: Shuichiro KITO, Koji KAWAGUCHI, Takeshi SATO, Hisato SAWANAMI, Takuya ODA
-
Patent number: 9040536Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: July 31, 2014Date of Patent: May 26, 2015Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20140336197Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventors: Makoto OKADA, Shuichiro SATO, Kenji KAWADE, Kotaro GOTANDA, Atsushi SHINBO, Youichi NAKANO, Hideo KOBAYASHI
-
Patent number: 8829000Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: September 14, 2012Date of Patent: September 9, 2014Assignee: ASKA Pharmaceutical Co., Ltd.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20130225572Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: September 14, 2012Publication date: August 29, 2013Inventors: Makoto OKADA, Shuichiro SATO, Kenji KAWADE, Kotaro GOTANDA, Atsushi SHINBO, Youichi NAKANO, Hideo KOBAYASHI
-
Patent number: 8299080Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: December 12, 2007Date of Patent: October 30, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Patent number: 8207203Abstract: This invention offers isoxazole derivatives represented by the following formula (I) in which R1 and R2 each stands for hydrogen, lower alkyl, amino and the like; R3 stands for substituted or unsubstituted aryl or hetero aryl; R4 stands for hydrogen or lower alkyl; R5 stands for substituted or unsubstituted phenyl, furyl and the like; and Y stands for —CH2—, —CO—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof which exhibit excellent p38MAPkinase-inhibiting action with reduced side-effects, and are useful for treating such diseases as chronic rheumatoid arthritis, ulcerative colitis and the like.Type: GrantFiled: June 26, 2007Date of Patent: June 26, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Koichi Hasumi, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Jun-ya Kato, Jun Sato, Hiroyuki Suzuki, Hajime Asano, Mami Okada, Yasuhiro Matsumoto, Kazuhiko Shirota
-
Patent number: 8101624Abstract: The invention discloses quinazoline derivatives or salts thereof, which possess PDE9-inhibiting activity and are useful as treating agents of dysuria and the like, the derivatives being represented by the formula (I) in the formula, R1 stands for phenyl or aromatic heterocyclic group which are optionally substituted with 1-3 substituents selected from halogen, C1-6 alkyl, C1-6 haloalkyl containing 1-6 halogen atoms and C1-6 alkoxy; and n is an integer of 1-3.Type: GrantFiled: July 24, 2007Date of Patent: January 24, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Akira Asagarasu, Shuichiro Sato, Makoto Okada
-
Patent number: 7939536Abstract: The invention discloses isoxazole derivatives represented by a formula, in which R1 stands for hydrogen, lower alkyl, amino, halogen, lower alkoxy and the like, R2 stands for substituted or unsubstituted aryl and the like, R3 stands for hydrogen or lower alkyl, R4 stands for substituted or unsubstituted phenyl and the like, and Y stands for —CH2—, —CO—, —CH(CH3)—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof, which have excellent p38MAPkinase inhibitory action.Type: GrantFiled: December 27, 2005Date of Patent: May 10, 2011Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Koichi Hasumi, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Jun-ya Kato, Jun Sato, Hiroyuki Suzuki, Hajime Asano, Mami Okada, Yasuhiro Matsumoto, Kazuhiko Shirota
-
Publication number: 20100048556Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: December 12, 2007Publication date: February 25, 2010Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20090318478Abstract: The invention discloses quinazoline derivatives or salts thereof, which possess PDE9-inhibiting activity and are useful as treating agents of dysuria and the like, the derivatives being represented by the formula (I) in the formula, R1 stands for phenyl or aromatic heterocyclic group which are optionally substituted with 1-3 substituents selected from halogen, C1-6 alkyl, C1-6 haloalkyl containing 1-6 halogen atoms and C1-6 alkoxy; and n is an integer of 1-3.Type: ApplicationFiled: July 24, 2007Publication date: December 24, 2009Inventors: Akira Asagarasu, Shuichiro Sato, Makoto Okada
-
Publication number: 20090306145Abstract: This invention offers isoxazole derivatives represented by the following formula (I) in which R1 and R2 each stands for hydrogen, lower alkyl, amino and the like; R3 stands for substituted or unsubstituted aryl or hetero aryl; R4 stands for hydrogen or lower alkyl; R5 stands for substituted or unsubstituted phenyl, furyl and the like; and Y stands for —CH2—, —CO—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof which exhibit excellent p38MAPkinase-inhibiting action with reduced side-effects, and are useful for treating such diseases as chronic rheumatoid arthritis, ulcerative colitis and the like.Type: ApplicationFiled: June 26, 2007Publication date: December 10, 2009Inventors: Koichi Hasumi, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Jun-ya Kato, Jun Sato, Hiroyuki Suzuki, Hajime Asano, Mami Okada, Yasuhiro Matsumoto, Kazuhiko Shirota
-
Publication number: 20090192164Abstract: The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient.Type: ApplicationFiled: June 26, 2007Publication date: July 30, 2009Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Koichi Hasumi, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Jun-ya Kato, Jun Sato, Hiroyuki Suzuki, Hajime Asano, Mami Okada, Yasuhiro Matsumoto, Kazuhiko Shirota
-
Publication number: 20080114003Abstract: The invention discloses isoxazole derivatives represented by a formula, in which R1 stands for hydrogen, lower alkyl, amino, halogen, lower alkoxy and the like, R2 stands for substituted or unsubstituted aryl and the like, R3 stands for hydrogen or lower alkyl, R4 stands for substituted or unsubstituted phenyl and the like, and Y stands for —CH2—, —CO—, —CH(CH3)—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof, which have excellent p38MAPkinase inhibitory action.Type: ApplicationFiled: December 27, 2005Publication date: May 15, 2008Inventors: Koichi Hasumi, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Junya Kato, Jun Sato, Hiroyuki Suzuki, Hajime Asano, Mami Okada, Yasuhiro Matsumoto, Kazuhiko Shirota
-
Patent number: 7087624Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)-(A)n-Y, —CH2—CH(R4)-(A)n-Y, —CO-B1-A-Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group.Type: GrantFiled: October 27, 2003Date of Patent: August 8, 2006Assignee: Teikoju Hormone Mfg. Co., Ltd.Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Publication number: 20040087628Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)-(A)n —Y, —CH2 —CH(R4)-(A)n—Y, —CO—B1-A-Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.Type: ApplicationFiled: October 27, 2003Publication date: May 6, 2004Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Patent number: 6667325Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)—(A)n—Y, —CH2—CH(R4)—(A)n—Y, —CO—B1—A—Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.Type: GrantFiled: December 3, 2001Date of Patent: December 23, 2003Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Patent number: 6511997Abstract: Aminopyrazole derivatives represented by formula (I), or salts thereof, wherein X1 and X2 are each a hydrogen atom or a halogen atom, or X1 and X2 may be united together to form a lower alkylenedioxy group, Q is a pyridyl group or a quinolyl group, R1 is a hydrogen atom, a substituted or unsubstituted lower alkyl or aryl group, R2 is a hydrogen atom, a lower alkyl group, or an aralkyl group, and R3 represents a hydrogen atom, an organic sulfonyl group, or —C(═Y)—R4 in which R4 is a hydrogen atom or an organic residue and Y is an oxygen or sulfur atom, provided that, when R3 is a hydrogen atom, R1 is a group other than a hydrogen atom and R2 is a hydrogen atom. These amimopyrazole derivatives or their salts have excellent p38MAP kinase inhibiting activities and are hence useful in the prevention or treatment of diseases associated with tumor necrosis sis factor &agr;, interleukin 1, interleukin 6 or cyclooxygenase II.Type: GrantFiled: June 22, 2001Date of Patent: January 28, 2003Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Patent number: 6291485Abstract: 4,5-Dihydro-[1H]-benz[g]indazole-3-carboxylic acid derivatives represented by the following formula, or their salts, have excellent antagonism to endothelin receptors and are useful as preventives or remedies for diseases such as hypertension, angina pectoris, myocardial infarction, brain infarction, cerebrovascular contraction, renal insufficiency, hepatic dysfunction, arteriosclerosis and post-PTCA restenosis. wherein Ar represents an optionally substituted aryl group, and R1 represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group or an optionally substituted heterocyclic group.Type: GrantFiled: January 10, 2000Date of Patent: September 18, 2001Assignees: Teikoku Hormone Mfg. Co., Ltd.Inventors: Hiroshi Azuma, Haruo Yamashita, Katsuyuki Keino, Shuji Ota, Takahisa Saito, Shuichiro Sato, Hidehisa Hamasaki, Katsura Suzuki, Akiko Sugimoto